A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

被引：0

作者：

Sara M. Balch

Ines Vaz-Luis

Tianyu Li

Nabihah Tayob

Esha Jain

Karla Helvie

Jorge E. Buendia-Buendia

Erin Shannon

Steven J. Isakoff

Nadine M. Tung

Ian E. Krop

Nancy U. Lin

Nikhil Wagle

Rachel A. Freedman

机构：

[1] The Broad Institute of MIT and Harvard,Department of Data Sciences

[2] Department of Medical Oncology,undefined

[3] Dana-Farber Cancer Institute,undefined

[4] Institut Gustave Roussy,undefined

[5] Unit INSERM 981,undefined

[6] Dana-Farber Cancer Institute,undefined

[7] Massachusetts General Hospital,undefined

[8] Harvard Medical School,undefined

[9] Beth Israel Deaconess Medical Center,undefined

[10] Cellarity,undefined

[11] Inc.,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 189卷

关键词：

HER2+ breast cancer; Trastuzumab; Pertuzumab; Eribulin mesylate;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：411 / 423

页数：12

共 50 条

[31] Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
McIntyre, Kristi
O'Shaughnessy, Joyce
Schwartzberg, Lee
Glueck, Stefan
Berrak, Erhan
Song, James X.
Cox, David
Vahdat, Linda T.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (02) : 321 - 328
[32] Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Kristi McIntyre
Joyce O’Shaughnessy
Lee Schwartzberg
Stefan Glück
Erhan Berrak
James X. Song
David Cox
Linda T. Vahdat
Breast Cancer Research and Treatment, 2014, 146 : 321 - 328
[33] Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Kim, Min Chong
Kang, Su Hwan
Choi, Jung Eun
Bae, Young Kyung
JOURNAL OF BREAST CANCER, 2020, 23 (05) : 484 - 497
[34] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Garnock-Jones, Karly P.
Keating, Gillian M.
Scott, Lesley J.
BIODRUGS, 2010, 24 (03) : 207 - 209
[35] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
Karly P. Garnock-Jones
Gillian M. Keating
Lesley J. Scott
BioDrugs, 2010, 24 : 207 - 209
[36] Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)
Lin, N.
Danso, M. A.
David, A. K.
Muscato, J.
Rayson, D.
Houck, W. A., III
Ellis, C.
DeSilvio, M.
Garofalo, A.
Nagarwala, Y.
Winer, E.
CANCER RESEARCH, 2012, 72
[37] Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient
Freedman, Rachel A.
Muss, Hyman B.
JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 2 - 7
[38] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Kalinsky, K.
Chi, D-C
Lee, S.
Bhardwaj, A.
Makower, D.
Cigler, T.
Crew, K. D.
Hershman, D. L.
Califano, A.
Silva, J.
Maurer, M.
CANCER RESEARCH, 2016, 76
[39] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Kalinsky, Kevin
Chi, Dow-Chung
Lee, Shing
Tiersten, Amy
Makower, Della
Chuang, Ellen
Crew, Katherine D.
Hershman, Dawn L.
Silva, Jose
Califano, Andrea
Maurer, Matthew
CANCER RESEARCH, 2015, 75
[40] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Matthew Kearney
Lauren Franks
Shing Lee
Amy Tiersten
Della F. Makower
Tessa Cigler
Prabhjot Mundi
Dow-Chung Chi
Anupama Goel
Pam Klein
Eleni Andreopoulou
Joseph Sparano
Meghna Trivedi
Melissa Accordino
Andrea Califano
Dawn L. Hershman
Jose Silva
Kevin Kalinsky
Breast Cancer Research and Treatment, 2021, 189 : 177 - 185

← 1 2 3 4 5 →